Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
← catalyst calendarNCT07745361 · readout ≤ 438 d
Sponsored by Monte Rosa Therapeutics, Inc (industry) · GLUE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
25estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Castration-Resistant Prostate Cancer (CRPC)
- Castration-Resistant Prostate Cancer
- Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
Interventions
- Drug: Oral MRT-2359
- Drug: Apalutamide
Primary outcome
what the primary-completion date above is the date OFAssess the efficacy of MRT-2359 combined with apalutamide
measured 14 months
Permalink · GLUE's whole pipeline · Catalyst calendar · Every registered study · What changed